Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Treatment with monoclonal antibody specific for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, has emerged as an effective therapy for the treatment of metastatic melanoma. Although subject to debate, current models favor a mechanism of activity involving blockade of the inhibitory activity of CTLA-4 on both effector (T eff) and regulatory (T reg) T cells, resulting in enhanced antitumor effector T cell activity capable of inducing tumor regression. We demonstrate, however, that the activity of anti-CTLA-4 antibody on the T reg cell compartment is mediated via selective depletion of T reg cells within tumor lesions. Importantly, T reg cell depletion is dependent on the presence of Fcγ receptor-expressing macrophages within the tumor microenvironment, indicating that T reg cells are depleted in trans in a context-dependent manner. Our results reveal further mechanistic insight into the activity of anti-CTLA-4-based cancer immunotherapy, and illustrate the importance of specific features of the local tumor environment on the final outcome of antibody-based immunomodulatory therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-CTLA-4 and anti-PD-1 antibodies have been successful in depleting tumor-infiltrating Tregs and increasing the effector T cell (Teff) to Treg ratio in the tumor microenvironment (Curran et al., 2010; Quezada et al., 2006; Simpson et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, multiple studies have been confirmed that antibody-dependent cell-mediated cytotoxicity of Treg also substantially contributes to the antitumor activity of ipilimumab [128–130].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [129]
Experimental — accuracy not yet measuredIn the citing paper
“CTLA-4 is also expressed on Tregs; targeting CTLA-4 could theoretically lead to Treg cell dysfunction or depletion as has been demonstrated in mice (Simpson et al., 2013), though not all data support this notion in humans”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Simpson et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 6×
“The lack of additive or synergistic therapeutic benefit of the combination of –CTLA-4 with peptide vaccination in the recent phase III clinical trial (Hodi et al., 2010) could at least be partially explained by a lack of vaccine-mediated impact on appropriate accessory cell populations.”
BackgroundInfluentialSelf-citationFoxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
BackgroundIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · cited 1×
“–CTLA-4 therapy has demonstrated significant antitumor activity in preclinical tumor models (Leach et al., 1996; van Elsas et al., 1999; Quezada et al., 2011) and in clinical trials as an immunotherapy for metastatic melanoma (Hodi et al., 2010; Robert et al., 2011).”
BackgroundSelf-citationCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 2×
“, 2001), the demonstration that CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et a…”
BackgroundFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 14×
“In mice, ADCC is regulated predominantly by the low-affinity receptors FcRIII and FcRIV (Nimmerjahn et al., 2005; Nimmerjahn et al., 2010; Setiady et al., 2010), and to a lesser extent by the highaffinity FcRI (Fossati-Jimack et al., 2000; Tedder et al., 2006; Hamaguchi et al., 2006).”
BackgroundInfluentialSelf-citationTakahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233 · cited 1×
“…CD4+Foxp3+ regulatory T cells (T reg cell) express high levels of CTLA-4 led to the suggestion that –CTLA-4 directly impacts the T reg cell compartment, either by mediating depletion, or by affecting their suppressive activity (Read et al., 2000, 2006; Takahashi et al., 2000; Wing et al., 2008).”
BackgroundRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice
Kim, J. M., Rasmussen, J. P., & Rudensky, A. Y. (2007) · Nature Immunology · doi:10.1038/ni1428 · Cited by 1,820 · cited 1×
“Widespread depletion of T reg cells can induce multiple autoimmune pathologies (Fontenot et al., 2003; Kim et al., 2007).”
Background
Cited by
Items 401–500 of 1,000
Fujita, M., Yamaguchi, R., Hasegawa, T., Shimada, S., Arihiro, K., Hayashi, S., Maejima, K., Nakano, K., Fujimoto, A., Ono, A., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102659 · Cited by 87
Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors
Donnadieu, E., Dupré, L., Pinho, L. G., & Cotta-de-Almeida, V. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.1mr0520-746r · Cited by 87
Lehmann, B., Biburger, M., Brückner, C., Ipsen-Escobedo, A., Gordan, S., Lehmann, C. H. K., Voehringer, D., Winkler, T., Schaft, N., Dudziak, D., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aah6413 · Cited by 92
“Moreover, it was demonstrated that one underlying mechanism of the immunomodulatory activity of CTLA4-specific antibodies is through intratumoral depletion of regulatory T cells via myeloid effector cells (40).”
BackgroundZammarchi, F., Havenith, K., Bertelli, F., Vijayakrishnan, B., Chivers, S., & van Berkel, P. H. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000860 · Cited by 85
Gauttier, V., Pengam, S., Durand, J., Biteau, K., Mary, C., Morello, A., Néel, M., Porto, G., Teppaz, G., Thépenier, V., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135528 · Cited by 88
Boumelha, J., Trécesson, S. D. C., Law, E. K., Romero-Clavijo, P., Coelho, M. A., Ng, K. W., Mugarza, E., Moore, C., Rana, S., Caswell, D. R., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0325 · Cited by 87
“8D), as previously reported (28).”
CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma
Yu, G., Bu, L., Zhao, Y., Mao, L., Deng, W., Wu, T., Zhang, W., & Sun, Z. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1151594 · Cited by 89
“Nevertheless, targeting CTLA4 may still have an effect on other cells populations such as Treg.(45) Additionally, a recent study indicated that ipilimumab enhances cetuximab-mediated ADCC by eliminating intratumor Treg in HNSCC.”
BackgroundImmune checkpoint therapy for pancreatic cancer
Johansson, H., Andersson, R. E., Bauden, M. P., Hammes, S., Holdenrieder, S., & Ansari, D. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i43.9457 · Cited by 91
van Hooren, L., Sandin, L. C., Moskalev, I., Ellmark, P., Dimberg, A., Black, P. C., Tötterman, T. H., & Mangsbo, S. M. (2016) · European Journal of Immunology · doi:10.1002/eji.201646583 · Cited by 89
IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development
Li, A., Herbst, R. H., Canner, D., Schenkel, J. M., Smith, O. C., Kim, J. Y., Hillman, M., Bhutkar, A., Cuoco, M. S., Rappazzo, C. G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.120 · Cited by 83
“, 2013), and antibodies directed against CTLA-4 act in part by depleting Tregs (Simpson et al., 2013).”
BackgroundWeeden, C. E., Gayevskiy, V., Marceaux, C., Batey, D., Tan, T., Yokote, K., Ribera, N. T., Clatch, A., Christo, S. N., Teh, C. E., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.019 · Cited by 85
Quirk, S. K., Shure, A. K., & Agrawal, D. K. (2015) · Translational research · doi:10.1016/j.trsl.2015.06.005 · Cited by 86
“This correlates with a previously discussed publication (12).”
Immune checkpoint inhibitors: therapeutic advances in melanoma.
Márquez‐Rodas, I., Cerezuela-Fuentes, P., Soria, A., Berrocal, A., Riso, A. A., González‐Cao, M., & Martín‐Algarra, S. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.10.27 · Cited by 93
Lai, C., August, S., Albibas, A., Behar, R., Cho, S., Polak, M. E., Theaker, J. M., MacLeod, A. S., French, R. R., Glennie, M. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2614 · Cited by 91
CTLA-4 (CD152): A versatile receptor for immune-based therapy
Lingel, H., & Brunner-Weinzierl, M. C. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101298 · Cited by 80
Crosby, E. J., Wei, J., Yang, X. Y., Lei, G., Wang, T., Liu, C.-X., Agarwal, P., Korman, A. J., Morse, M. A., Gouin, K., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1421891 · Cited by 84
“the depletion of Tregs specifically from the TNBC tumor microenvironment.(40,44,45) Treg elimination with the tumor and systemic blockade of CTLA4C Tregs may also explain the large”
BackgroundResultLatest Advances in Targeting the Tumor Microenvironment for Tumor Suppression
Laplagne, C., Domagala, M., Le Naour, A., Quemerais, C., Hamel, D., Fournié, J.-J., Couderc, B., Bousquet, C., Ferrand, A., & Poupot, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194719 · Cited by 72
“Using an experimental model of Fc-receptor deficient mice, the anti-tumor effect of the anti-CTLA4 antibody was shown to be dependent on antibody-dependent cellular cytotoxicity of TI T-regs instead of re-activating conventional T-cells [135].”
MethodSavoia, P., Astrua, C., & Fava, P. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1129478 · Cited by 90
In-situ tumor vaccination: Bringing the fight to the tumor
Pierce, R. H., Campbell, J. S., Pai, S. I., Brody, J., & Kohrt, H. E. K. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1049779 · Cited by 82
“In addition, CTLA-4 is strongly expressed on Tregs and ipilimumab, which is an IgG1 mAb with antibody-dependent cell-mediated cytotoxic (ADCC) activity, may act, in part, by killing Tregs through ADCC.(88)”
BackgroundNeoepitopes as Cancer Immunotherapy Targets: Key Challenges and Opportunities
Brennick, C. A., George, M. M., Corwin, W. L., Srivastava, P. K., & Ebrahimi-Nik, H. (2017) · Immunotherapy · doi:10.2217/imt-2016-0146 · Cited by 83
Allies or Enemies—The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment
Haas, L., & Obenauf, A. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02746 · Cited by 89
“Despite many encouraging results, TAM targeting still needs further investigation, since it was recently shown that classical monocytes and macrophages are required for better response to checkpoint inhibition in mouse models (99, 100) and that binding of antibodies to FC receptors of macrophages contributes to the su…”
BackgroundDual targeting of CTLA-4 and CD47 on T reg cells promotes immunity against solid tumors
Zhang, A., Ren, Z., Tseng, K., Liu, X., Li, H., Lu, C., Cai, Y., Minna, J. D., & Fu, Y. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg8693 · Cited by 81
Yofe, I., Landsberger, T., Yalin, A., Solomon, I., Costoya, C., Demane, D. F., Shah, M., David, E., Borenstein, C., Barboy, O., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00447-1 · Cited by 83
“Within the CD4 compartment, the CD4 Cxcr6 fraction was increased relative to all lymphoid cells (Fig.”
BackgroundInfluentialSelf-citationClinical Development of Immune Checkpoint Inhibitors
Ito, A., Kondo, S., Tada, K., & Kitano, S. (2015) · BioMed Research International · doi:10.1155/2015/605478 · Cited by 87
“Tumor cells harness Hindawi Publishing Corporation BioMed Research International Volume 2015, Article ID 605478, 12 pages http://dx.doi.org/10.1155/2015/605478 these suppressive effects as one of their “immunoediting” mechanisms [2].”
BackgroundInfluentialPentcheva-Hoang, T., Simpson, T. R., Montalvo-Ortiz, W., & Allison, J. P. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0104 · Cited by 79
Self-citationRole of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress
Myint, Z. W., & Goel, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0454-7 · Cited by 81
“The inhibition of this receptor-ligand interaction using an antiCTLA-4 antibody results in the reactivation and proliferation of T cells and also decreases the immunosuppressive Treg cells in the tumor microenvironment [4].”
Bispecific Antibodies in the Treatment of Hematologic Malignancies
Duell, J., Lammers, P. E., Djuretic, I. M., Chunyk, A. G., Alekar, S., Jacobs, I. A., & Gill, S. I. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1396 · Cited by 82
“In murine tumor models, treatment with an anti– CTLA- 4 antibody led to a reduction in the number of intra tumoral Tregs and better tumor control.(61) More recently, administration of an anti- CD27 antibody in mouse tumor models and in patients with advanced solid tumors resulted in antitumor activity associated with…”
BackgroundB Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
Willsmore, Z. N., Harris, R. J. C., Crescioli, S., Hussein, K., Kakkassery, H., Thapa, D., Cheung, A., Chauhan, J., Bax, H. J., Chenoweth, A. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.622442 · Cited by 84
Pacella, I., & Piconese, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01889 · Cited by 83
MacGregor, H. L., Sayad, A., Elia, A., Wang, B. X., Katz, S. R., Shaw, P. A., Clarke, B. A., Crome, S. Q., Robert-Tissot, C., Bernardini, M. Q., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0816-5 · Cited by 82
“CTLA-4 blocking antibodies have also been shown to facilitate the depletion of Tregs [4] in an FcγR-dependent manner in addition to relieving inhibition on the CD28 costimulatory pathway [5].”
BackgroundThe Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy
Neophytou, C. M., Pierides, C., Christodoulou, M., Costeas, P., Kyriakou, T.-C., & Papageorgis, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00899 · Cited by 83
“A subject of debate, however, is whether the anti-CTLA-4 antibodies act in favor of anti-tumor immune responses or not, in terms of targeting the CTLA-4 molecules expressed on regulatory T-cells (Tregs).”
BackgroundInfluentialProcureur, A., Simonaggio, A., Bibault, J., Oudard, S. M., & Vano, Y. A. (2021) · Cancers · doi:10.3390/cancers13040678 · Cited by 82
“Thus, unmodified IgG1 antibodies like ipilimumab (human IgG1/kappa) induce a greater Treg depletion in mouse model than IgG2 antibodies like tremelimumab (human IgG2/kappa) [64,65].”
BackgroundRational combinations of immunotherapeutics that target discrete pathways
Spranger, S., & Gajewski, T. F. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-16 · Cited by 82
“In addition to the activity of anti-CTLA-4 mAb on lowering the threshold for activation of T cells in lymphoid organs, recent data suggest that some anti-CTLA-4 mAbs also can deplete Tregs within the tumor microenvironment [47].”
BackgroundKunert, A., Straetemans, T., Govers, C., Lamers, C., Mathijssen, R. H. J., Sleijfer, S., & Debets, R. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00363 · Cited by 89
Tan, S., Zhang, C. W.-H., & Gao, G. F. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.29 · Cited by 80
Sharma, N., Vacher, J., & Allison, J. P. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819004116 · Cited by 75
“We showed earlier by using surface plasmon resonance analysis that unlike the 9H10 clone of anti–CTLA-4, which is a Syrian hamster IgG2b, the Armenian hamster IgG1 clone 4F10 of anti– CTLA-4 does not show any appreciable binding to FcγRIV (5).”
BackgroundMethodResultInfluentialSelf-citationImmune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation
Yang, H., Yao, Z., Zhou, X., Zhang, W., Zhang, X., & Zhang, F. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108377 · Cited by 74
Balatoni, T., Mohos, A., Papp, E., Sebestyén, T., Liszkay, G., Oláh, J., Varga, A., Lengyel, Z., Emri, G., Gaudi, I., et al. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2072-1 · Cited by 76
González-Navajas, J. M., Fan, D. D., Yang, S., Yang, F. M., Lozano‐Ruiz, B., Shen, L., & Lee, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625783 · Cited by 84
Chang, D.-K., Peterson, E., Sun, J., Goudie, C., Drapkin, R., Liu, J. F., Matulonis, U. A., Zhu, Q. K., & Marasco, W. A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1090075 · Cited by 79
“(ADCP) that is dependent on the presence of FcgR-expressing macrophages within the tumor microenvironment.(59) The clini-”
BackgroundB cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment
Chiaruttini, G., Mele, S., Opzoomer, J. W., Crescioli, S., Ilieva, K. M., Lacy, K. E., & Karagiannis, S. N. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1294296 · Cited by 76
“Given the array of Fc receptors expressed by effector cells, including those infiltrating tumors, it may be important to understand how antibodies and effector cells that form part of tumor immune surveillance may influence antitumor immunity, and how they affect the efficacy of therapeutic antibodies.(118) Furthermor…”
BackgroundCTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils
Zheng, X., Zhang, N., Qian, L., Wang, X., Fan, P., Kuai, J., Lin, S., Liu, C., Jiang, W., Qin, S., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32829 · Cited by 81
Yokoyama, Y., Estok, T. M., & Wild, R. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0282 · Cited by 81
Wei, T., Zhang, J., Qin, Y., Wu, Y. C., Zhu, L. X., Lu, L., Tang, G., & Shen, Q. (2015) · Europe PMC (PubMed Central) · Cited by 75
Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation
Togashi, Y., & Nishikawa, H. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_58 · Cited by 85
“Analyses of anti-CTLA-4 antibodies in mouse models revealed that the anti-tumor efficacy was dependent on depletion of CTLA-4-expressing Tregs in tumors through the antibody-dependent cellular cytotoxic (ADCC) activity of the anti-CTLA-4 antibody; depletion of Fc function totally abrogated the anti-tumor effect of the…”
BackgroundMochel, M. C., Ming, M. E., Imadojemu, S. E., Gangadhar, T. C., Schuchter, L. M., Elenitsas, R., Payne, A. S., & Chu, E. Y. (2016) · Journal of Cutaneous Pathology · doi:10.1111/cup.12735 · Cited by 77
Sanseviero, E., O’Brien, E. M., Karras, J. R., Shabaneh, T. B., Aksoy, B. A., Xu, W., Zheng, C., Yin, X., Xu, X., Karakousis, G. C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0386 · Cited by 80
“Anti–CTLA-4 clone 9H10 has been shown to bind to FcgRIV, andmediate depletion of Tregs infiltrating B16 tumors in an FcgRIV-dependentmanner (5).”
BackgroundInfluentialDiversity of immune checkpoints in cancer immunotherapy
Guo, Z., Zhang, R., Yang, A., & Zheng, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121285 · Cited by 83
Differentiation fate of a stem-like CD4 T cell controls immunity to cancer
Cardenas, M. A., Prokhnevska, N., Sobierajska, E., Gregorova, P., Medina, C. B., Valanparambil, R. M., Greenwald, R., del Balzo, L., Bilen, M. A., Joshi, S. S., et al. (2024) · Nature · doi:10.1038/s41586-024-08076-7 · Cited by 81
Reprogramming the tumor microenvironment to enhance adoptive cellular therapy
Beavis, P. A., Slaney, C. Y., Kershaw, M. H., Gyorki, D. E., Neeson, P. J., & Darcy, P. K. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.003 · Cited by 81
Harnessing Fc receptor biology in the design of therapeutic antibodies
Sondermann, P., & Szymkowski, D. E. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.005 · Cited by 77
CAR ‐T cell therapy in melanoma: A future success story?
Simon, B., & Uslu, U. (2018) · Experimental Dermatology · doi:10.1111/exd.13792 · Cited by 80
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
Karaki, S., Anson, M., Tran, T., Giusti, D., Blanc, C., Oudard, S. M., & Tartour, É. (2016) · Vaccines · doi:10.3390/vaccines4040037 · Cited by 76
Immune checkpoint inhibitors: new strategies to checkmate cancer
Wilson, R. A. M., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B. (2018) · Clinical and Experimental Immunology · doi:10.1111/cei.13081 · Cited by 70
“Anti-CTLA-4 antibodies can also bind Fcγ receptors (FcγRs) to mediate antibody-dependent cell-mediated cytotoxicity against CTLA-4 Tregs, leading to their selective depletion [40-43].”
BackgroundSensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
Zemek, R. M., Chin, W. L., Nowak, A. K., Millward, M., Lake, R., & Lesterhuis, W. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00223 · Cited by 75
Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors
Pawłowska, A., Rekowska, A. K., Kuryło, W., Pańczyszyn, A., Kotarski, J., & Wertel, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310859 · Cited by 79
Stecher, C., Battin, C., Leitner, J. M., Zettl, M., Grabmeier‐Pfistershammer, K., Höeller, C., Zlabinger, G. J., & Steinberger, P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00572 · Cited by 77
“In this context, it should be noted that recent work suggests that the therapeutic efficacy of CTLA-4 antibodies may not be primarily due to neutralization of CTLA-4-mediated T cell inhibition but is owed to its ability to deplete regulatory T cells in the tumor microenvironment (37, 38).”
BackgroundImmunotherapy for prostate cancer: recent developments and future challenges
Schweizer, M. T., & Drake, C. G. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9479-8 · Cited by 80
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
Shklovskaya, E., & Rizos, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136741 · Cited by 78
“Such antibodies can bind to tumors and trigger indirect tumor killing via ADCC by engaging cytotoxic macrophages and/or NK cells [329].”
BackgroundImmunotherapy for hepatocellular carcinoma: Recent advances and future targets
Yu, S. J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108387 · Cited by 73
Regulatory T cells in solid tumor immunotherapy: effect, mechanism and clinical application
Pan, Y., Zhou, H., Sun, Z., Zhu, Y., Zhang, Z., Han, J., Liu, Y., & Wang, Q. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07544-w · Cited by 74
Emerging roles of regulatory T cells in tumour progression and metastasis
Halvorsen, E. C., Mahmoud, S., & Bennewith, K. L. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9529-x · Cited by 80
“When administered separately, these agents were unable to prolong survival; however, when given in combination, they significantly reduced tumour progression and increased the Teff/Treg ratio [151].”
BackgroundICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40–Mediated Tumor Rejection
Metzger, T. C., Long, H., Potluri, S., Pertel, T., Bailey-Bucktrout, S. L., Lin, J. C.-Y., Fu, T., Sharma, P., Allison, J. P., & Feldman, R. M. R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3412 · Cited by 73
Self-citationSugawara, K., Iwai, M., Ito, H., Tanaka, M., Seto, Y., & Todo, T. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.004 · Cited by 72
“Previous studies demonstrated the discrepancy between the preclinical and clinical efficacy of anti-CTLA-4 immunotherapy.(25,49,50) In particular, CTLA-4 inhibition has the capacity to selectively deplete intratumoral Tregs in preclinical murine models(25,49) but does not have this effect in human tumors.”
ResultTallerico, R., Cristiani, C. M., Staaf, E., Garofalo, C., Sottile, R., Capone, M., de Coaña, Y. P., Madonna, G., Palella, E., Wolodarski, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1261242 · Cited by 73
Rudqvist, N.-P., Charpentier, M., Lhuillier, C., Wennerberg, E., Spada, S., Sheridan, C. K., Zhou, X. K., Zhang, T., Formenti, S. C., Sims, J. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40844-3 · Cited by 76
Targeting the tumor microenvironment to enhance antitumor immune responses
Van der Jeught, K., Bialkowski, L., Daszkiewicz, L., Broos, K., Goyvaerts, C., Renmans, D., Van Lint, S., Heirman, C., Thielemans, K., & Breckpot, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3204 · Cited by 68
“In this regard, it has recently been shown in mice that treatment with anti-CTLA-4 monoclonal antibodies might deplete Tregs in the tumor microenvironment [235].”
BackgroundKelton, W., Mehta, N., Charab, W., Lee, J., Lee, C., Kojima, T., Kang, T. H., & Georgiou, G. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.10.017 · Cited by 79
“In these experiments, we used MDA-MB-453 cells expressing moderate levels of Her2 antigen, as these cells have been reported to be resistant to elimination by ADCP using trastuzumab in vitro (Narayan et al., 2009).”
BackgroundInfluentialRecent advances in understanding antitumor immunity
Munhoz, R. R., & Postow, M. A. (2016) · F1000Research · doi:10.12688/f1000research.9356.1 · Cited by 84
Scurr, M., Pembroke, T., Bloom, A., Roberts, D., Thomson, A., Smart, K., Bridgeman, H., Adams, R., Brewster, A., Jones, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2579 · Cited by 68
Porta, C., Sica, A., & Riboldi, E. (2018) · The FEBS Journal · doi:10.1111/febs.14288 · Cited by 69
What, Why, Where, and When: Bringing Timing to Immuno-Oncology
Rothschilds, A. M., & Wittrup, K. D. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.11.003 · Cited by 72
Targeting myeloid cells using nanoparticles to improve cancer immunotherapy
Amoozgar, Z., & Goldberg, M. S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.007 · Cited by 73
Bell, R. B., Leidner, R. S., Crittenden, M. R., Curti, B. D., Feng, Z., Montler, R. D., Gough, M. J., Fox, B. A., Weinberg, A. D., & Urba, W. J. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.11.009 · Cited by 73
ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity
Haines, B. B., Denslow, A., Grzesik, P., Lee, J. S., Farkaly, T., Hewett, J., Wambua, D., Kong, L., Behera, P., Jacques, J., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0609 · Cited by 73
“The anti-mouse CTLA-4 blocker was from the 9D9 mAb (22) on a Fc effector–competent mIgG2a backbone.”
Beavis, P. A., Henderson, M. A., Giuffrida, L., Davenport, A. J., Petley, E. V., House, I. G., Lai, J., Sek, K., Milenkovski, N., John, L. B., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0291 · Cited by 68
“Further studies have shown that CTLA-4 blockade modulates both Treg and non-Treg compartments (18, 39, 40), although none of these studies could exclude the possibility that anti–CTLA-4 activates CD4þFoxp3– cells indirectly throughmodulation of CD8þ or Foxp3þ T cells.”
BackgroundFujiwara, Y., Mittra, A., Naqash, A. R., & Takebe, N. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.11 · Cited by 87
“depletes tumor-infiltrating Tregs in the melanoma mouse model, which expressed granulocyte macrophage colony-stimulating factor and Fcγ receptor on macrophages was involved with depletion of Tregs by an anti-CTLA-4 antibody([94]).”
BackgroundDegroote, H., Vandierendonck, A., Geerts, A. M., Vlierberghe, H. V., & Devisscher, L. (2018) · Journal of Immunology Research · doi:10.1155/2018/7819520 · Cited by 69
“The e ffi cacy of anticytotoxic T lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibodies in a melanoma mouse model and humans is code-fi ned by elimination of regulatory T cells by TAM targeting via antibody-dependent cellular cytotoxicity [16 – 18 , 45 ].”
BackgroundDammeijer, F. F., Lau, S. P., van Eijck, C. H. J., van der Burg, S. H., & Aerts, J. G. J. V. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.011 · Cited by 75
Lewis, K. E., Selby, M., Masters, G. R., Valle, J., Dito, G., Curtis, W., García, R., Mink, K. A., Waggie, K. S., Holdren, M. S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1377873 · Cited by 69
“7E), consistent with enhanced antitumor responses, may be due in part to depletion of Tregs and expansion of Teffs.(26,35) Treg”
BackgroundLim, E. L., Cugliandolo, F. M., Rosner, D. R., Gyori, D., Roychoudhuri, R., & Okkenhaug, K. (2018) · JCI Insight · doi:10.1172/jci.insight.120626 · Cited by 66
“Anti–CTLA-4 antibody therapy has additionally been reported to deplete regulatory T cells (Tregs) in some contexts (4).”
BackgroundObradovic, A., Ager, C., Turunen, M., Nirschl, T., Khosravi-Maharlooei, M., Iuga, A., Jackson, C. M., Yegnasubramanian, S., Tomassoni, L., Fernandez, E. C., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.04.003 · Cited by 66
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
Yamazaki, N., Kiyohara, Y., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Tsutsumida, A., Yoshikawa, S., Okuyama, R., Ito, Y., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2873-x · Cited by 64
Endogenous Stimuli‐Activatable Nanomedicine for Immune Theranostics for Cancer
Wang, W., Jin, Y., Liu, X., Chen, F., Zheng, X., Liu, T., Yang, Y., & Yu, H. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100386 · Cited by 71
White, A. L., Dou, L., Chan, H. T. C., Field, V. L., Mockridge, C. I., Moss, K., Williams, E. L., Booth, S. G., French, R. R., Potter, E. A., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303204 · Cited by 69
Berman, D., Korman, A., Peck, R., Feltquate, D., Lonberg, N., & Canetta, R. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.017 · Cited by 61
Current status of immunotherapy
Suzuki, S., Ishida, T., Yoshikawa, K., & Ueda, R. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv201 · Cited by 71
“A reduction of Treg in the tumor site followed by a decrease of tumor size in tumor-bearing mice infused with anti-CTLA-4 mAb was reported (111).”
BackgroundPD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond
Ishida, Y. (2020) · Cells · doi:10.3390/cells9061376 · Cited by 68
“In the experimental mouse studies in which different anti-mouse CTLA-4 monoclonal IgG antibodies (either natural or recombinant) with distinct Fc structures were compared, those with higher affinity to Fc-gamma receptors (FcγRs) showed the stronger Treg-depleting and anti-tumor activities [31,32].”
BackgroundImmunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
Felice, F. D., Marchetti, C., Palaia, I., Musio, D., Muzii, L., Tombolini, V., & Panici, P. B. (2015) · Journal of Immunology Research · doi:10.1155/2015/191832 · Cited by 69
“It has been proposed that human IgG1 (the ipilimumab subclass) binds with a higher affinity to FcγRs than human IgG2 (the subclass of tremelimumab) does [35], therefore suggesting that tremelimumab might determine a CTLA-4 antibody mediated Treg-cell depletion to a lesser extent [36, 37].”
BackgroundVille, S., Poirier, N., Blancho, G., & Vanhove, B. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00411 · Cited by 66
Rashidian, M., Wang, L., Edens, J. G., Jacobsen, J. T., Hossain, I., Wang, Q., Victora, G. D., Vasdev, N., Ploegh, H. L., & Liang, S. H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201507596 · Cited by 65
How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?
Liu, Y., & Zheng, P. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.10.009 · Cited by 67
“However, recent studies from us and others have called for a reappraisal of the anti-CTLA-4 checkpoint blockade hypothesis [4-7].”
BackgroundResultParadigm shift in oncology: targeting the immune system rather than cancer cells
Shekarian, T., Valsesia‐Wittmann, S., Caux, C., & Marabelle, A. (2015) · Mutagenesis · doi:10.1093/mutage/geu073 · Cited by 64
Unlocking the Complexities of Tumor-Associated Regulatory T Cells
Chao, J. L., & Savage, P. A. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701188 · Cited by 69
“(9) demonstrated in mice that administration of distinct anti–CTLA-4 Ab clones induced the depletion of intratumoral Treg cells without impacting intratumoral conventional T cells or Treg cells outside of the tumor, resulting in slowed outgrowth of transplantable melanomas.”
BackgroundIL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy
Zhu, J., Liu, J.-Q., Shi, M., Cheng, X., Ding, M., Zhang, J. C., Davis, J. P., Varikuti, S., Satoskar, A. R., Lu, L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98745 · Cited by 65
Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy
Khelil, M. B., Godet, Y., Abdeljaoued, S., Borg, C., Adotévi, O., & Loyon, R. (2022) · Cancers · doi:10.3390/cancers14010260 · Cited by 68
“As CTLA-4 molecules are expressed by both CD4+ effector T cells and Tregs, this dependence to the CD4+ T subset could be explained by the role of help assured by CD4+ T cells or the effect of the depletion of the Treg population [154,155].”
BackgroundTargeting tumor-infiltrating tregs for improved antitumor responses
Qin, D., Zhang, Y., Shu, P., Lei, Y., Li, X., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1325946 · Cited by 77
Macrophages in Colorectal Cancer Liver Metastases
Cortese, N., Soldani, C., Franceschini, B., Barbagallo, M., Marchesi, F., Torzilli, G., & Donadon, M. (2019) · Cancers · doi:10.3390/cancers11050633 · Cited by 61
“In particular, in melanoma, both in preclinical and in clinical settings, treatment with antibodies directed against CTLA-4 and glucocorticoid-induced TNFR-related protein (GITR) induced Treg depletion in an fragment crystallizable (Fc)-γ receptor (FcγR) -mediated manner [36,37].”
BackgroundCCL22 Signaling in the Tumor Environment
Röhrle, N., Knott, M. M. L., & Anz, D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-36667-4_8 · Cited by 72
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy
Goleva, E., Lyubchenko, T. A., Kraehenbuehl, L., Lacouture, M. E., Leung, D. Y. M., & Kern, J. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.003 · Cited by 64
Metadata
- Authors
- Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., Peggs, K. S., Ravetch, J. V., Allison, J. P., & Quezada, S. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Rockefeller University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Ludwig Center for Cancer Immunotherapy, Department of Immunology, and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065 3
- University College London (GB)
- Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London WC1E 6DD, UK 6
- Department of Immunology, Juntendo University School of Medicine, 113-8421 Tokyo, Japan 5
- Corresponding author
- Allison, James P.
- Quezada, Sergio A.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-07-29
- Volume
- 210
- Issue
- 9
- Pages
- 1695-1710
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3754863
- OpenAlex
- W2121080857
- Cited by
- 1,472
- References
- 60
- Citations by year
- 2026: 66 · 2025: 79 · 2024: 97 · 2023: 89 · 2022: 112 · 2021: 140 · 2020: 158 · 2019: 125 · 2018: 122 · 2017: 126 · 2016: 121 · 2015: 135 · 2014: 85 · 2013: 15
- FWCI
- 63.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research UK (12100)
- Canadian Institutes of Health Research
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, CTLA-4, regulatory T cells, melanoma, Fc gamma receptor, tumor-infiltrating macrophages, T cell depletion, tumor microenvironment, cancer immunotherapy, metastatic melanoma
- MeSH terms
- Animals, Cell Membrane, Clone Cells, Lymph Nodes, Lymphocyte Depletion, Melanoma, Mice, Inbred C57BL, Phagocytes, Signal Transduction, CD4 Antigens, Granulocyte-Macrophage Colony-Stimulating Factor, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Receptors, IgG, CD8-Positive T-Lymphocytes, Lymphocyte Count, Antibodies, Blocking, CD11b Antigen, T-Lymphocytes, Regulatory, Mice, TNF-Related Apoptosis-Inducing Ligand, Fas Ligand Protein, Tumor Microenvironment, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.